Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Z Safferman

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The Annals of Pharmacotherapy|March 1, 1992
Central nervous system toxicity after abrupt monoamine oxidase inhibitor switch: a case reportA Z Safferman, S J Masiar
The Psychiatric Quarterly|January 1, 1992
Clinical profile of clozapine: adverse reactions and agranulocytosisJ A Lieberman, A Z Safferman
DICP : the Annals of Pharmacotherapy|October 1, 1990
A case of lisinopril-induced lithium toxicityC M Baldwin, A Z Safferman
Psychopharmacology Bulletin|January 1, 1995
Do white-cell count spikes predict agranulocytosis in clozapine recipients?J M Alvir, J A Lieberman, A Z Safferman
The Journal of Clinical Psychiatry|September 1, 1993
Does clozapine cause tardive dyskinesia?J M Kane, M G Woerner, S Pollack, et al.
The New England Journal of Medicine|July 15, 1993
Clozapine-induced agranulocytosis. Incidence and risk factors in the United StatesJ M Alvir, J A Lieberman, A Z Safferman, et al.
The Journal of Clinical Psychiatry|September 1, 1994
The use of clozapine in neurologic disordersA Z Safferman, J M Kane, J S Aronowitz, et al.
The Journal of Clinical Psychiatry|September 1, 1994
Clozapine, negative symptoms, and extrapyramidal side effectsJ M Kane, A Z Safferman, S Pollack, et al.
Psychopharmacology Bulletin|January 1, 1995
A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effectsS Pollack, J A Lieberman, W W Fleischhacker, et al.
The Journal of Clinical Psychiatry|September 1, 1994
Clozapine dose in the United States and Europe: implications for therapeutic and adverse effectsW W Fleischhacker, M Hummer, M Kurz, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Annals of Pharmacotherapy|March 1, 1992
Central nervous system toxicity after abrupt monoamine oxidase inhibitor switch: a case reportA Z Safferman, S J Masiar
The Psychiatric Quarterly|January 1, 1992
Clinical profile of clozapine: adverse reactions and agranulocytosisJ A Lieberman, A Z Safferman
DICP : the Annals of Pharmacotherapy|October 1, 1990
A case of lisinopril-induced lithium toxicityC M Baldwin, A Z Safferman
Psychopharmacology Bulletin|January 1, 1995
Do white-cell count spikes predict agranulocytosis in clozapine recipients?J M Alvir, J A Lieberman, A Z Safferman
The Journal of Clinical Psychiatry|September 1, 1993
Does clozapine cause tardive dyskinesia?J M Kane, M G Woerner, S Pollack, et al.
The New England Journal of Medicine|July 15, 1993
Clozapine-induced agranulocytosis. Incidence and risk factors in the United StatesJ M Alvir, J A Lieberman, A Z Safferman, et al.
The Journal of Clinical Psychiatry|September 1, 1994
The use of clozapine in neurologic disordersA Z Safferman, J M Kane, J S Aronowitz, et al.
The Journal of Clinical Psychiatry|September 1, 1994
Clozapine, negative symptoms, and extrapyramidal side effectsJ M Kane, A Z Safferman, S Pollack, et al.
Psychopharmacology Bulletin|January 1, 1995
A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effectsS Pollack, J A Lieberman, W W Fleischhacker, et al.
The Journal of Clinical Psychiatry|September 1, 1994
Clozapine dose in the United States and Europe: implications for therapeutic and adverse effectsW W Fleischhacker, M Hummer, M Kurz, et al.
Pageof 2